Drug intelligence / Profile preview

NX2601

Development stage: Unknown
Lead developer: NEXTGEN Bioscience

Overview

NX2601 is an early-stage drug candidate being developed by NEXTGEN Bioscience in partnership with SK chemicals. Currently in the discovery stage, the therapeutic indication, molecular target, and modality of NX2601 remain undisclosed. The candidate is part of NEXTGEN Bioscience's pipeline, which leverages its proprietary AI-driven drug discovery platform, Fibrain, to identify and optimize novel therapeutics for autoimmune and fibrotic diseases.

Beyond the preview

Go deeper on NX2601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NX2601.

Explore the full profile